<\/p>\n
<\/p>\n\n\nActivities<\/a>\n\nEvents<\/a><\/li>\nNews<\/a><\/li>\n<\/ul>\n<\/li>\nOrganization<\/a>\n\nOrganisational Chart<\/a><\/li>\n<\/ul>\n<\/li>\nRegulation<\/a>\n\nInternational Conventions and Agreements<\/a><\/li>\nLaws and Ordinances<\/a><\/li>\nDecrees<\/a><\/li>\nOrders<\/a><\/li>\nInterministerial Orders<\/a><\/li>\nDecisions<\/a><\/li>\nOfficial Gazettes<\/a><\/li>\nGuides & Guidelines<\/a><\/li>\n<\/ul>\n<\/li>\nInstitutes<\/a>\n\nSaidal Group<\/a><\/li>\nNational Agency for Pharmaceutical Products<\/a><\/li>\n<\/ul>\n<\/li>\nObtain License<\/a>\n\nLicensing Procedures<\/a><\/li>\n<\/ul>\n<\/li>\nNotes & Alerts<\/a>\n\nInformation Notes<\/a><\/li>\nAlerts<\/a><\/li>\n<\/ul>\n<\/li>\nDownload<\/a>\n\nDownload<\/a><\/li>\n<\/ul>\n<\/li>\nContact<\/a>\n\nContact Us<\/a><\/li>\n<\/ul>\n<\/li>\nEN<\/a>\n\nAr<\/a><\/li>\nFr<\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/nav>\n <\/p>\n\n \n \n \n 06\/06\/2026: <\/strong>Lancement des travaux de l'atelier technique sur l'auto-\u00e9valuation du syst\u00e8me r\u00e9glementaire national de pharmaceutique, avec la participation des responsables des minist\u00e8res de l'Industrie pharmaceutique et de la Sant\u00e9, ainsi que de l'Agence nationale des produits pharmaceutiques et d'experts de l'Organisation mondiale de la Sant\u00e9.<\/div><\/div><\/div><\/li>\n <\/li>\n <\/li>\n 16\/04\/2026: <\/strong>Le ministre de l'Industrie pharmaceutique, Dr wassim Kouidri, a re\u00e7u, au si\u00e8ge du minist\u00e8re de l'industrie pharmaceutique, le pr\u00e9sident du Syndicat national des pharmaciens priv\u00e9s (SNAPO), Sami Tirache, accompagn\u00e9 de membres du bureau national,<\/div><\/div><\/div><\/li>\n 16\/04\/2026: <\/strong>Le ministre de l'Industrie pharmaceutique, Dr Wassim kuidri a re\u00e7u le directeur r\u00e9gional du Fonds des Nations Unies pour l'enfance (UNICEF) pour le Moyen-Orient et l'Afrique du Nord (MENA), M. Edouard Beigbeder,<\/span><\/span><\/span>\u00a0<\/span>en pr\u00e9sence de la repr\u00e9sentante du bureau de l'UNICEF en Alg\u00e9rie, Mme Katerina Johansson, et de la d\u00e9l\u00e9gation qui les accompagnait. \u00a0<\/span><\/p> <\/div><\/div><\/div><\/li>\n 15\/04\/2026: <\/strong>Le ministre de l'Industrie pharmaceutique, Dr Wassim kuidri, accompagn\u00e9 de la ministre, du haut-commissairiat \u00e0 la num\u00e9risation, Mme Mariam Ben Mouloud, et du ministre des Postes et des T\u00e9l\u00e9communications, M. Sid Ali Zarrouki, une r\u00e9union de coordination visant \u00e0 examiner le projet de syst\u00e8me informatique destin\u00e9 \u00e0 assurer le suivi de l'approvisionnement du march\u00e9 national en produits pharmaceutiques et \u00e0 garantir le bon fonctionnement du service public.<\/span> \u00a0<\/p> <\/div><\/div><\/div><\/li>\n 09\/04\/2026: <\/strong>Le ministre de l\u2019Industrie pharmaceutique, Dr Wassim Kouidri, a re\u00e7u au si\u00e8ge du minist\u00e8re le ministre de la Sant\u00e9 du Mozambique, M. Ussene Hilario Isse, en pr\u00e9sence de l\u2019ambassadeur du Mozambique en Alg\u00e9rie, M. Antonio Namburete. Cette rencontre a \u00e9t\u00e9 l\u2019occasion d\u2019\u00e9voquer les perspectives de coop\u00e9ration bilat\u00e9rale entre les deux pays dans le de l\u2019industrie pharmaceutique.<\/span><\/div><\/div><\/div><\/li>\n 07\/04\/2026: <\/strong>Le ministre de l\u2019Industrie pharmaceutique, le Dr Wassim Kouidri, supervise, au niveau de la commune d\u2019Ouled Djellal, l\u2019inauguration d\u2019une pharmacie de vente de m\u00e9dicaments, d\u00e9nomm\u00e9e \u00ab Pharmacies Saidal \u00bb, relevant du groupe public Saidal.<\/div><\/div><\/div><\/li>\n 01\/04\/2026: <\/strong>Le ministre de l'Industrie pharmaceutique, M. Wassim Kuidri, a re\u00e7u au si\u00e8ge du minist\u00e8re la vice-pr\u00e9sidente de la Commission de l\u2019Union africaine, Mme Selma Malika Haddadi, qui \u00e9tait accompagn\u00e9e du chef du d\u00e9partement Sant\u00e9 de l\u2019Union africaine, le Dr Adamo Issa. \u00a0<\/div> \u00a0<\/div> <\/div> <\/div> <\/div> <\/div> \u00a0<\/div> <\/div><\/div><\/div><\/li>\n <\/ul>\n <\/div>\n \n <\/div>\n<\/div>\n <\/p>\n\n\n\n<\/td>\n\nNational List of Pharmaceutical Products for Human Use\u2014 June 30, 2026<\/strong><\/a><\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<\/a>Youtube\u00a0<\/a><\/strong><\/td>\n<\/a><\/strong>X-twitter\u00a0<\/a><\/strong><\/td>\n<\/strong><\/p>\nFacebook<\/a><\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\n <\/p>\nsite map<\/a><\/strong><\/p>\n <\/p>\n\n\n\n\nconsultation notices<\/a><\/h4>\n<\/th>\n\nE-participation<\/a><\/h4>\n<\/th>\n\nQuality POLICY AND COMMITMENT<\/a><\/h4>\n<\/th>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\nPharmaceutical Industry Policy \u00a0<\/span><\/p>\n <\/p>\n\n\n\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/tr>\n\nAxis 1 : Ensuring the continuous availability of pharmaceutical products, with a particular focus on essential medicines.\n<\/span><\/p>\nThrough the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels.<\/p>\n<\/td>\nAxis2 :Implementation of tools and a regulatory framework to ensure quality, efficiency, and safety\n<\/span>\nThe National Agency for Pharmaceutical Products ANPP is strengthened in human and material resources, the drug registration and medical device approval commissions, sits on the intersectoral economic committee for medicines as well as the committee of clinical experts.<\/td>\n\nAxis 3 :\nDeveloping the national pharmaceutical industry as a wealth-generating sector and promoting investment.<\/a><\/h4>\nThrough the implementation of a new pricing procedure, the prioritization of the registration of generic medicines and similar biotherapeutic products, and the improved management of raw material import programmes.<\/p>\n<\/td>\nAxis 4 :Guaranteeing equitable and affordable access to pharmaceutical products for all citizens\n<\/span><\/p>\nBy expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/nav>\n<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
\u00a0<\/span><\/p> <\/div><\/div><\/div><\/li>\n 15\/04\/2026: <\/strong>Le ministre de l'Industrie pharmaceutique, Dr Wassim kuidri, accompagn\u00e9 de la ministre, du haut-commissairiat \u00e0 la num\u00e9risation, Mme Mariam Ben Mouloud, et du ministre des Postes et des T\u00e9l\u00e9communications, M. Sid Ali Zarrouki, une r\u00e9union de coordination visant \u00e0 examiner le projet de syst\u00e8me informatique destin\u00e9 \u00e0 assurer le suivi de l'approvisionnement du march\u00e9 national en produits pharmaceutiques et \u00e0 garantir le bon fonctionnement du service public.<\/span> \u00a0<\/p> <\/div><\/div><\/div><\/li>\n 09\/04\/2026: <\/strong>Le ministre de l\u2019Industrie pharmaceutique, Dr Wassim Kouidri, a re\u00e7u au si\u00e8ge du minist\u00e8re le ministre de la Sant\u00e9 du Mozambique, M. Ussene Hilario Isse, en pr\u00e9sence de l\u2019ambassadeur du Mozambique en Alg\u00e9rie, M. Antonio Namburete. Cette rencontre a \u00e9t\u00e9 l\u2019occasion d\u2019\u00e9voquer les perspectives de coop\u00e9ration bilat\u00e9rale entre les deux pays dans le de l\u2019industrie pharmaceutique.<\/span><\/div><\/div><\/div><\/li>\n 07\/04\/2026: <\/strong>Le ministre de l\u2019Industrie pharmaceutique, le Dr Wassim Kouidri, supervise, au niveau de la commune d\u2019Ouled Djellal, l\u2019inauguration d\u2019une pharmacie de vente de m\u00e9dicaments, d\u00e9nomm\u00e9e \u00ab Pharmacies Saidal \u00bb, relevant du groupe public Saidal.<\/div><\/div><\/div><\/li>\n 01\/04\/2026: <\/strong>Le ministre de l'Industrie pharmaceutique, M. Wassim Kuidri, a re\u00e7u au si\u00e8ge du minist\u00e8re la vice-pr\u00e9sidente de la Commission de l\u2019Union africaine, Mme Selma Malika Haddadi, qui \u00e9tait accompagn\u00e9e du chef du d\u00e9partement Sant\u00e9 de l\u2019Union africaine, le Dr Adamo Issa. \u00a0<\/div> \u00a0<\/div> <\/div> <\/div> <\/div> <\/div> \u00a0<\/div> <\/div><\/div><\/div><\/li>\n <\/ul>\n <\/div>\n \n <\/div>\n<\/div>\n <\/p>\n\n\n\n<\/td>\n\nNational List of Pharmaceutical Products for Human Use\u2014 June 30, 2026<\/strong><\/a><\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n<\/a>Youtube\u00a0<\/a><\/strong><\/td>\n<\/a><\/strong>X-twitter\u00a0<\/a><\/strong><\/td>\n<\/strong><\/p>\nFacebook<\/a><\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\n <\/p>\nsite map<\/a><\/strong><\/p>\n <\/p>\n\n\n\n\nconsultation notices<\/a><\/h4>\n<\/th>\n\nE-participation<\/a><\/h4>\n<\/th>\n\nQuality POLICY AND COMMITMENT<\/a><\/h4>\n<\/th>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\nPharmaceutical Industry Policy \u00a0<\/span><\/p>\n <\/p>\n\n\n\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/tr>\n\nAxis 1 : Ensuring the continuous availability of pharmaceutical products, with a particular focus on essential medicines.\n<\/span><\/p>\nThrough the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels.<\/p>\n<\/td>\nAxis2 :Implementation of tools and a regulatory framework to ensure quality, efficiency, and safety\n<\/span>\nThe National Agency for Pharmaceutical Products ANPP is strengthened in human and material resources, the drug registration and medical device approval commissions, sits on the intersectoral economic committee for medicines as well as the committee of clinical experts.<\/td>\n\nAxis 3 :\nDeveloping the national pharmaceutical industry as a wealth-generating sector and promoting investment.<\/a><\/h4>\nThrough the implementation of a new pricing procedure, the prioritization of the registration of generic medicines and similar biotherapeutic products, and the improved management of raw material import programmes.<\/p>\n<\/td>\nAxis 4 :Guaranteeing equitable and affordable access to pharmaceutical products for all citizens\n<\/span><\/p>\nBy expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/nav>\n<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
\u00a0<\/p> <\/div><\/div><\/div><\/li>\n
Facebook<\/a><\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\n <\/p>\nsite map<\/a><\/strong><\/p>\n <\/p>\n\n\n\n\nconsultation notices<\/a><\/h4>\n<\/th>\n\nE-participation<\/a><\/h4>\n<\/th>\n\nQuality POLICY AND COMMITMENT<\/a><\/h4>\n<\/th>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\nPharmaceutical Industry Policy \u00a0<\/span><\/p>\n <\/p>\n\n\n\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/tr>\n\nAxis 1 : Ensuring the continuous availability of pharmaceutical products, with a particular focus on essential medicines.\n<\/span><\/p>\nThrough the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels.<\/p>\n<\/td>\nAxis2 :Implementation of tools and a regulatory framework to ensure quality, efficiency, and safety\n<\/span>\nThe National Agency for Pharmaceutical Products ANPP is strengthened in human and material resources, the drug registration and medical device approval commissions, sits on the intersectoral economic committee for medicines as well as the committee of clinical experts.<\/td>\n\nAxis 3 :\nDeveloping the national pharmaceutical industry as a wealth-generating sector and promoting investment.<\/a><\/h4>\nThrough the implementation of a new pricing procedure, the prioritization of the registration of generic medicines and similar biotherapeutic products, and the improved management of raw material import programmes.<\/p>\n<\/td>\nAxis 4 :Guaranteeing equitable and affordable access to pharmaceutical products for all citizens\n<\/span><\/p>\nBy expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/nav>\n<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
site map<\/a><\/strong><\/p>\n <\/p>\n\n\n\n\nconsultation notices<\/a><\/h4>\n<\/th>\n\nE-participation<\/a><\/h4>\n<\/th>\n\nQuality POLICY AND COMMITMENT<\/a><\/h4>\n<\/th>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/p>\nPharmaceutical Industry Policy \u00a0<\/span><\/p>\n <\/p>\n\n\n\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/tr>\n\nAxis 1 : Ensuring the continuous availability of pharmaceutical products, with a particular focus on essential medicines.\n<\/span><\/p>\nThrough the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels.<\/p>\n<\/td>\nAxis2 :Implementation of tools and a regulatory framework to ensure quality, efficiency, and safety\n<\/span>\nThe National Agency for Pharmaceutical Products ANPP is strengthened in human and material resources, the drug registration and medical device approval commissions, sits on the intersectoral economic committee for medicines as well as the committee of clinical experts.<\/td>\n\nAxis 3 :\nDeveloping the national pharmaceutical industry as a wealth-generating sector and promoting investment.<\/a><\/h4>\nThrough the implementation of a new pricing procedure, the prioritization of the registration of generic medicines and similar biotherapeutic products, and the improved management of raw material import programmes.<\/p>\n<\/td>\nAxis 4 :Guaranteeing equitable and affordable access to pharmaceutical products for all citizens\n<\/span><\/p>\nBy expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/nav>\n<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Pharmaceutical Industry Policy \u00a0<\/span><\/p>\n <\/p>\n\n\n\n<\/th>\n<\/th>\n<\/th>\n<\/th>\n<\/tr>\n\nAxis 1 : Ensuring the continuous availability of pharmaceutical products, with a particular focus on essential medicines.\n<\/span><\/p>\nThrough the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels.<\/p>\n<\/td>\nAxis2 :Implementation of tools and a regulatory framework to ensure quality, efficiency, and safety\n<\/span>\nThe National Agency for Pharmaceutical Products ANPP is strengthened in human and material resources, the drug registration and medical device approval commissions, sits on the intersectoral economic committee for medicines as well as the committee of clinical experts.<\/td>\n\nAxis 3 :\nDeveloping the national pharmaceutical industry as a wealth-generating sector and promoting investment.<\/a><\/h4>\nThrough the implementation of a new pricing procedure, the prioritization of the registration of generic medicines and similar biotherapeutic products, and the improved management of raw material import programmes.<\/p>\n<\/td>\nAxis 4 :Guaranteeing equitable and affordable access to pharmaceutical products for all citizens\n<\/span><\/p>\nBy expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/nav>\n<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Through the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels.<\/p>\n<\/td>\n
Through the implementation of a new pricing procedure, the prioritization of the registration of generic medicines and similar biotherapeutic products, and the improved management of raw material import programmes.<\/p>\n<\/td>\n
By expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/nav>\n<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
<\/a>Digital services satisfaction survey <\/strong><\/a><\/p>\n <\/p>\nPlateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Plateforme\n<\/span><\/p>\n\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
\u00a0<\/span><\/p>\n\n\n\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n\n\n<\/a><\/td>\n<\/tr>\n\n\nPlateform \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644 – \u0625\u0646\u062a\u0627\u062c\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Online submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices.\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\nNote N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Note N\u00b0 25\/MIPP\/DPDIPER\/2023<\/a><\/strong><\/td>\n\nPlateform \u00ab\u00a0\u0631\u0624\u064a\u0629\u00a0\u00bb<\/a><\/h3>\nmproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n\nPlateforme \u00ab\u00a0\u062a\u0628\u0627\u062f\u0644\u00a0\u00bb<\/a><\/h3>\nOnline submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\nEmail : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
mproves visibility on the status of medicine stocks throughout the supply chain through:\n1-Monthly stock declarations;<\/b>\n2-Reporting of provisional programs;<\/b>\n3-Monthly reporting on implementation progress.<\/b> ……..More information<\/a><\/td>\n
Online submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals:<\/p>\n
Email : tabadol@miph.gov.dz<\/strong><\/p>\n <\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
<\/b>Note N\u00b0 09\/DSID\/MIP\/2023<\/a><\/strong><\/p>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n<\/a><\/p>\n<\/h3>\nCollection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Collection of legal texts\n<\/span><\/p>\nRegulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Regulatory reform involves all stages of drug manufacturing, including facilitating investment, good distribution practices and export support.<\/span><\/a><\/p>\n <\/p>\n <\/p>\nOnline services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Online services<\/a><\/span><\/p>\n\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
\u00a0Substances and drugs with psychotropic properties<\/span><\/strong><\/p>\n <\/p>\n\n\n\n<\/a><\/td>\n<\/a><\/td>\n<\/a><\/td>\n<\/tr>\n\n\nApplication for authorization to transport psychotropic substances<\/a>\n<\/a><\/strong>Note N\u00b0 936\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n\nQuarterly and annual inventory declaration<\/strong><\/a><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/h6>\n<\/td>\n\nDeclaration and justification of discrepancies in physical stocks<\/a><\/strong><\/h6>\nNote N\u00b0 937\/MIPP\/DAPR<\/strong><\/a>\/2023<\/strong><\/a><\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nDeclarations<\/span><\/p>\n <\/p>\n\n\n\n\n
Declarations<\/span><\/p>\n <\/p>\n\n\n\n\n
![\"\"](\"https:\/\/www.miph.gov.dz\/fr\/wp-content\/uploads\/2025\/10\/entete-EN.jpg\")
<\/p>\n<\/p>\n